Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results

Cancer

Volumn 75, Issue 2, 1995, Pages 552-559

  Akaza, Hideyuki ^a   Hinotsu, Shiro ^a   Aso, Yoshio ^b   Kakizoe, Tadao ^c   Kenkichi Koiso, M D , ^d  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NONE

Author keywords

bacillus Calmette Gu rin; carcinoma in situ of the bladder; immunotherapy; intravesical instillation; superficial bladder cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER PREVENTION; CANCER STAGING; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; BLADDER TUMOR; DISEASE COURSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0028870491     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H     Document Type: Article

References (19)

1. Intracavitary bacillus Calmette‐Guérin in the treatment of superficial bladder tumors
2. The use of bacillus Calmette‐Guérin in the therapy of bladder carcinoma in situ
3. BCG therapy alters the progression of superficial bladder cancer
4. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette‐Guérin for transitional cell carcinoma of the bladder
5. Multicenter study of superficial bladder cancer treated with intravesical bacillus Galmette‐Guérin or Adriamycin
6. A low dose bacillus Calmette‐Guérin regimen in superficial bladder cancer therapy: is it effective?
7. Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer: mitomycin C vs. BCG connaught vs. TUR alone [abstract]
8. Bacillus Calmette‐Guérin for superficial transitional cell carcinoma of the bladder
9. Experience with bacillus Calmette‐Guérin in patients with superficial bladder carcinoma
10. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder
11. Response criteria for urological cancer treatment
12. Analyses of the effects of intravesical bacillus Calmette‐Guérin (Tokyo 172 strain) therapy for superficial bladder cancer
13. Long‐term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin
14. Comparative analysis of short‐term and long‐term prophylactic intravesical chemotherapy of superficial bladder cancer: prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group
15. The biology and treatment of superficial bladder cancer
16. Optimal BCG treatment of superficial bladder cancer as defined by American trials
17. Requirement of a thymus dependent immune response for BCG‐mediated antitumor activity
18. Expression of antitumor response: role of attachment and viability of bacillus Calmette‐Guérin to bladder cancer cells
19. Serial multiple‐site biopsy in patients with bladder cancer